Tivic Health Systems, INC 10-Q quarterly reports

Valion Bio, Inc. (VBIO) reported substantial net losses and ongoing going concern uncertainties in its Q2 2026 Form 10-Q, while also addressing Nasdaq's minimum bid price non-compliance.

Valion Bio reports Q1 2026 financial results, highlighting its transition to a biopharmaceutical company and the expansion of its CDMO operations in San Antonio.

Tivic Health Systems, Inc. reported increased net losses and negative cash flow for Q3 2025, accelerating its pivot from consumer health to biopharmaceutical development while facing going concern doubts and manufacturing delays.

Tivic Health Systems reports a decrease in revenue for Q2 2025 due to reduced advertising spend, shifting focus to biopharma programs.

Tivic Health Systems reports a decrease in revenue for Q1 2025, shifting focus to biopharma and bioelectronic development with strategic acquisitions and financing activities.

Tivic Health Systems reported a decrease in revenue for the third quarter of 2024 compared to the same period last year, while also highlighting progress in their vagus nerve stimulation research and cost reduction efforts.

Tivic Health Systems reported a net loss of $2.7 million for the first half of 2024, while focusing on cost reduction and advancing its vagus nerve stimulation research.

Tivic Health Systems reported a net loss of $1.5 million for the first quarter of 2024, alongside a decrease in revenue and ongoing concerns about its ability to continue as a going concern.